Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
0.9950
-0.0150 (-1.49%)
At close: Feb 24, 2026, 4:00 PM EST
1.036
+0.041 (4.14%)
After-hours: Feb 24, 2026, 7:59 PM EST
Cocrystal Pharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
13.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| BioAtla | 11.00M |
| Traws Pharma | 2.85M |
| Iterum Therapeutics | 390.00K |
| BioCardia | 3.00K |
COCP News
- 5 days ago - Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 - GlobeNewsWire
- 2 months ago - Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - GlobeNewsWire
- 3 months ago - Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program - GlobeNewsWire
- 5 months ago - Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 5 months ago - Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire